Vimarsana
Biggest News Aggregation in the World

Page 37 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Group Today - Breaking & Trending Today

Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant - Vimarsana News

Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant

Published: October 23, 2023

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for ...

Source: pharmiweb.com
Related Topics:
United StatesLevi GarrawayKirti PandeySimon GoldsboroughThomas SchineckerLoren KalmGastroenterol HepatolNathalie AltermattKarsten KleineSileia UrechRebekka SchnellRoche GroupHead Of Global Product DevelopmentPfizer IncRoivant Sciences LtdTelavant Holdings IncDavis Polk WardwellFreshfields Bruckhaus DeringerTelavant HoldingsRoivant SciencesChief Medical OfficerGlobal ProductHart Scott Rodino Antitrust Improvements ActDavis PolkDow Jones Sustainability Indices
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant - Vimarsana News

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Published: October 23, 2023

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a...

Source: marketscreener.com
Related Topics:
City OfUnited KingdomStephanie LeeThomas SchineckerFrank TortiMatt GlineGastroenterol HepatolDavis Polk WardwellRoche GroupTelavant Holdings IncPfizer IncSecurities ExchangeFreshfields Bruckhaus DeringerExchange CommissionRoivant Sciences LtdRoivant SciencesTelavant HoldingsVant ChairHart Scott Rodino Antitrust Improvements ActDavis PolkInflammatory Bowel DiseasesSecurities ActSecurities Exchange ActRisk FactorsInflamm Bowel
BioNTech to Report Third Quarter Financial Results and - Vimarsana News

BioNTech to Report Third Quarter Financial Results and

Published: October 23, 2023

MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the...

Source: globenewswire.com
Related Topics:
Fosun PharmaCompany Innovation Series OnRoche GroupInnovation SeriesInvestor RelationsNew TechnologiesNasdaq BntxBiontech Se3 WebcastInnovation Series DayEbcast 3 Quartal
Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings - Vimarsana News

Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings

Published: October 23, 2023

Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction.

Source: nbcmiami.com
Related Topics:
United StatesThomas SchineckerRoche GroupTelavant HoldingsRoivant SciencesSouth Florida
Roche to acquire Telavant Holdings for $7.1bn - Vimarsana News

Roche to acquire Telavant Holdings for $7.1bn

Published: October 23, 2023

Roche is acquiring Telavant Holdings, a company owned by Roivant and Pfizer, to get access to its treatment for inflammatory bowel disease.

Source: siliconrepublic.com
Related Topics:
Thomas SchineckerMatt GlineTelavant HoldingsRoche Group